Brief: Relmada Therapeutics Reports First Quarter 2023 Financial Results
11/05/2023 21:58
May 11 (Reuters) - Relmada Therapeutics Inc RLMD.O :
* RELMADA THERAPEUTICS PROVIDES CORPORATE UPDATE AND REPORTS
FIRST
QUARTER 2023 FINANCIAL RESULTS
* RELMADA THERAPEUTICS INC - NET LOSS FOR THREE MONTHS ENDED
MARCH
31, 2023, WAS $26.3 MILLION, OR $0.87 PER BASIC AND DILUTED
SHARE
Source text for Eikon: ID:nPn9c5MDka
Further company coverage: RLMD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Relmada Therapeutics
See all newsRelmada Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Relmada Therapeutics Q2 EPS USD -0.11
Relmada Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia As Chief Business Officer
Brief: Relmada Therapeutics - Increases Authorized Common Stock To 200 Million Shares From 150 Million